265 related articles for article (PubMed ID: 25275557)
21. Interferon gamma-inducible protein 10: a predictive marker of successful treatment response in hepatitis C virus/HIV-coinfected patients.
Zeremski M; Markatou M; Brown QB; Dorante G; Cunningham-Rundles S; Talal AH
J Acquir Immune Defic Syndr; 2007 Jul; 45(3):262-8. PubMed ID: 17414926
[TBL] [Abstract][Full Text] [Related]
22. Deciphering the interleukin 28B variants that better predict response to pegylated interferon-α and ribavirin therapy in HCV/HIV-1 coinfected patients.
de Castellarnau M; Aparicio E; Parera M; Franco S; Tural C; Clotet B; Martínez MA
PLoS One; 2012; 7(2):e31016. PubMed ID: 22328925
[TBL] [Abstract][Full Text] [Related]
23. HCV kinetics, quasispecies, and clearance in treated HCV-infected and HCV/HIV-1-coinfected patients with hemophilia.
Shire NJ; Horn PS; Rouster SD; Stanford S; Eyster ME; Sherman KE;
Hepatology; 2006 Nov; 44(5):1146-57. PubMed ID: 17058240
[TBL] [Abstract][Full Text] [Related]
24. Effect of ribavirin and interferon beta on miRNA profile in the hepatitis C virus subgenomic replicon-bearing Huh7 cells.
Gong BD; Xie Q; Xiang XG; Wang L; Zhao GD; An FM; Wang H; Lin LY; Yu H; Bao SS
Int J Mol Med; 2010 Jun; 25(6):853-9. PubMed ID: 20428788
[TBL] [Abstract][Full Text] [Related]
25. Managing symptomatic drug-induced liver injury in HIV-hepatitis C virus-coinfected patients: a role for interferon.
McGovern BH; Birch C; Zaman MT; Bica I; Stone D; Quirk JR; Davis B; Zachary K; Basgoz N; Graeme-Cook F; Gandhi RT
Clin Infect Dis; 2007 Nov; 45(10):1386-92. PubMed ID: 17968840
[TBL] [Abstract][Full Text] [Related]
26. Complexity and catalytic efficiency of hepatitis C virus (HCV) NS3 and NS4A protease quasispecies influence responsiveness to treatment with pegylated interferon plus ribavirin in HCV/HIV-coinfected patients.
Aparicio E; Franco S; Parera M; Andrés C; Tural C; Clotet B; Martínez MA
J Virol; 2011 Jun; 85(12):5961-9. PubMed ID: 21471227
[TBL] [Abstract][Full Text] [Related]
27. Effects of alpha interferon treatment on intrinsic anti-HIV-1 immunity in vivo.
Abdel-Mohsen M; Deng X; Liegler T; Guatelli JC; Salama MS; Ghanem Hel-D; Rauch A; Ledergerber B; Deeks SG; Günthard HF; Wong JK; Pillai SK
J Virol; 2014 Jan; 88(1):763-7. PubMed ID: 24155399
[TBL] [Abstract][Full Text] [Related]
28. Telaprevir for HIV/hepatitis C virus-coinfected patients failing treatment with pegylated interferon/ribavirin (ANRS HC26 TelapreVIH): an open-label, single-arm, phase 2 trial.
Cotte L; Braun J; Lascoux-Combe C; Vincent C; Valantin MA; Sogni P; Lacombe K; Neau D; Aumaitre H; Batisse D; de Truchis P; Gervais A; Michelet C; Morlat P; Vittecoq D; Rosa I; Bertucci I; Chevaliez S; Aboulker JP; Molina JM;
Clin Infect Dis; 2014 Dec; 59(12):1768-76. PubMed ID: 25139963
[TBL] [Abstract][Full Text] [Related]
29. Short-term Treatment With Interferon Alfa Diminishes Expression of HIV-1 and Reduces CD4+ T-Cell Activation in Patients Coinfected With HIV and Hepatitis C Virus and Receiving Antiretroviral Therapy.
Morón-López S; Gómez-Mora E; Salgado M; Ouchi D; Puertas MC; Urrea V; Navarro J; Jou A; Pérez M; Tural C; Clotet B; Montaner LJ; Blanco J; Crespo M; Martinez-Picado J
J Infect Dis; 2016 Mar; 213(6):1008-12. PubMed ID: 26525407
[TBL] [Abstract][Full Text] [Related]
30. Ribavirin and interferon alter MMP-9 abundance in vitro and in HIV-HCV-coinfected patients.
Kennedy A; Hennessy M; Bergin C; Mulcahy F; Hopkins S; Spiers JP
Antivir Ther; 2011; 16(8):1237-47. PubMed ID: 22155905
[TBL] [Abstract][Full Text] [Related]
31. Ribavirin Concentrations Do Not Predict Sustained Virological Response in HIV/HCV-Coinfected Patients Treated with Ribavirin and Pegylated Interferon in the Swiss HIV Cohort Study.
Kovari H; Russmann S; Ledergerber B; Müller D; Rotger M; Velli P; Cavassini M; Ambrosioni J; Bregenzer A; Stöckle M; Bernasconi E; Rauch A; Speck RF;
PLoS One; 2015; 10(7):e0133879. PubMed ID: 26218843
[TBL] [Abstract][Full Text] [Related]
32. Variation in both IL28B and KIR2DS3 genes influence pegylated interferon and ribavirin hepatitis C treatment outcome in HIV-1 co-infection.
Keane C; O'Shea D; Reiberger T; Peck-Radosavljevic M; Farrell G; Bergin C; Gardiner CM
PLoS One; 2013; 8(6):e66831. PubMed ID: 23826153
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of pegylated interferon plus ribavirin in HIV and hepatitis C virus-coinfected patients with advanced immunosuppression.
Mira JA; Gutiérrez-Valencia A; Gil Ide L; Merino D; Rivero A; Ríos-Villegas MJ; Delgado M; González-Serrano M; Collado A; Torres-Tortosa M; Omar M; López-Ruz MA; Macías J; Arponen S; Pineda JA
Clin Infect Dis; 2009 Oct; 49(8):e84-91. PubMed ID: 19772388
[TBL] [Abstract][Full Text] [Related]
34. Concomitant highly active antiretroviral therapy leads to smaller decline and faster recovery of CD4+ cell counts during and after pegylated interferon plus ribavirin therapy in HIV-hepatitis C virus coinfected patients.
Reiberger T; Payer BA; Kosi L; Heil PM; Rieger A; Peck-Radosavljevic M;
J Infect Dis; 2011 Jun; 203(12):1802-6. PubMed ID: 21606538
[TBL] [Abstract][Full Text] [Related]
35. Impaired HCV clearance in HIV/HCV coinfected subjects treated with PegIFN and RBV due to interference of IFN signaling by IFNαR2a.
Lee YJ; Zhang X; Vazquez E; Shivasabesan G; Young HA; Murphy A; Wang H; Suffredini AF; Siebenlist U; Kottilil S
J Interferon Cytokine Res; 2014 Jan; 34(1):28-34. PubMed ID: 24171456
[TBL] [Abstract][Full Text] [Related]
36. High-throughput profiling of alpha interferon- and interleukin-28B-regulated microRNAs and identification of let-7s with anti-hepatitis C virus activity by targeting IGF2BP1.
Cheng M; Si Y; Niu Y; Liu X; Li X; Zhao J; Jin Q; Yang W
J Virol; 2013 Sep; 87(17):9707-18. PubMed ID: 23824794
[TBL] [Abstract][Full Text] [Related]
37. Hepatitis C virus genotype 4 responds better to pegylated interferon with ribavirin than genotype 1 in HIV-infected patients.
Mira JA; Rivero A; de Los Santos-Gil I; López-Cortés LF; Girón-González JA; Márquez M; Merino D; del Mar Viloria M; Téllez F; Ríos-Villegas MJ; Omar M; Rivero-Juárez A; Macías J; Pineda JA;
AIDS; 2012 Aug; 26(13):1721-4. PubMed ID: 22695304
[TBL] [Abstract][Full Text] [Related]
38. Role of pegylated interferon-alpha-2a and ribavirin concentrations in sustained viral response in HCV/HIV-coinfected patients.
Lopez-Cortes LF; Valera-Bestard B; Gutierrez-Valencia A; Ruiz-Valderas R; Jimenez L; Arizcorreta A; Terrón A; Viciana P
Clin Pharmacol Ther; 2008 Nov; 84(5):573-80. PubMed ID: 18596682
[TBL] [Abstract][Full Text] [Related]
39. Lack of interference between ribavirin and nucleosidic analogues in HIV/HCV co-infected individuals undergoing concomitant antiretroviral and anti-HCV combination therapy.
Landau A; Batisse D; Piketty C; Jian R; Kazatchkine MD
AIDS; 2000 Aug; 14(12):1857-8. PubMed ID: 10985327
[No Abstract] [Full Text] [Related]
40. Pharmacodynamics of PEG-IFN alpha differentiate HIV/HCV coinfected sustained virological responders from nonresponders.
Talal AH; Ribeiro RM; Powers KA; Grace M; Cullen C; Hussain M; Markatou M; Perelson AS
Hepatology; 2006 May; 43(5):943-53. PubMed ID: 16761329
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
